Aspirin and Colorectal Cancer Prevention: What the Latest Research Says

For years, aspirin has been investigated as a potential preventative measure against colorectal cancer. However, recent research has cast doubt on its widespread use for this purpose. While aspirin may offer benefits to specific populations, such as those with a genetic predisposition to the disease or those who have previously had colorectal cancer, the evidence suggests it doesn’t provide broad protection for the general population. This article examines the latest findings on aspirin and colorectal cancer risk, outlining the potential benefits, risks and what the research currently reveals.

Understanding Colorectal Cancer and Chemoprevention

Colorectal cancer (CRC) is the third most common cancer worldwide, accounting for 10% of all cancer diagnoses . It often develops from abnormal growths called colorectal adenomas (CRAs). Chemoprevention, the use of medications to reduce cancer risk, has been a focus of research, with nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin and ibuprofen being studied for their potential to prevent CRC. This is based on the understanding that chronic inflammation can contribute to tumor development.

What Does the Research Say About Aspirin and CRC?

A comprehensive review of studies, including data from nearly 125,000 individuals primarily in Europe and North America, suggests that daily aspirin use may not significantly reduce the risk of developing colorectal cancer in the general population after 5 to 15 years of follow-up .

Here’s a breakdown of the findings:

• New CRC Cases: Aspirin likely doesn’t affect the number of new CRC cases after 5-15 years. There is some uncertainty regarding a potential reduction in new cases after 15 years or more of aspirin use, but the evidence is not conclusive.
• CRC Mortality: Aspirin may slightly increase deaths from CRC in the initial 5-10 years, potentially by accelerating the growth of already advanced cancers. After 15 years or more, aspirin may reduce deaths, but this finding is also uncertain.
• Colorectal Adenomas (CRAs): The evidence regarding aspirin’s effect on the development of CRAs is inconclusive.

The Risks of Aspirin Use

While aspirin may not offer widespread protection against colorectal cancer, it’s crucial to consider the potential risks associated with its use:

• Serious Extracranial Hemorrhage: Aspirin increases the risk of serious bleeding outside the skull.
• Hemorrhagic Stroke: Aspirin likely increases the risk of bleeding in or around the brain.
• Overall Serious Side Effects: Aspirin does not appear to affect the overall number of serious side effects, but the specific risks of bleeding are significant.

Aspirin and Colorectal Cancer Recurrence

Recent research indicates that aspirin may play a role in reducing the risk of recurrence in patients who have already been treated for colorectal cancer, particularly those with specific genetic alterations. A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in January 2025 found that a daily dose of 160 mg of aspirin reduced recurrence rates in patients with stage I, II, or III rectal cancer, or stage II or III colon cancer, who had alterations in the PI3K signaling pathway . This benefit was observed in approximately one-third of patients with these genetic changes.

Who Might Benefit from Aspirin?

The current evidence suggests that aspirin may be beneficial for:

• Individuals with a Genetic Predisposition: People with conditions like Lynch syndrome have been shown to benefit from daily low-dose aspirin in reducing their risk of colorectal cancer.
• Those with a History of Colorectal Cancer: Aspirin may assist prevent recurrence in individuals who have previously been diagnosed and treated for the disease, especially those with PI3K pathway alterations.

The Bottom Line

The role of aspirin in colorectal cancer prevention remains complex. For the general population, the evidence does not support the routine use of aspirin to prevent the disease, given the potential risks of bleeding. However, individuals with specific genetic risk factors or a history of colorectal cancer may benefit from discussing aspirin use with their healthcare provider. Further research is needed to fully understand the long-term effects of aspirin and to explore other anti-inflammatory drugs for cancer prevention.